AR050044A1 - Anticuerpo especifico de il-4 - Google Patents
Anticuerpo especifico de il-4Info
- Publication number
- AR050044A1 AR050044A1 ARP050103199A ARP050103199A AR050044A1 AR 050044 A1 AR050044 A1 AR 050044A1 AR P050103199 A ARP050103199 A AR P050103199A AR P050103199 A ARP050103199 A AR P050103199A AR 050044 A1 AR050044 A1 AR 050044A1
- Authority
- AR
- Argentina
- Prior art keywords
- ser
- gly
- amino acid
- acid sequence
- tyr
- Prior art date
Links
- 108090000978 Interleukin-4 Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 36
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 abstract 6
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 abstract 2
- 102000055229 human IL4 Human genes 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un anticuerpo específico de IL-4 humana, el cual se enlaza a la IL-4 humana con una constante de disociacion Kd igual o menor que 800 pM. Reivindicacion 2: Un anticuerpo de la reivindicacion 1, el cual tiene un primer dominio que comprende, en secuencia, las regiones hipervariables CDR1, CDR2, y CDR3, y un segundo dominio que comprende, en secuencia, las regiones hipervariables CDR1', CDR2', y CDR3, seleccionado a partir del grupo que consiste en un anticuerpo en donde: a) la CDR1 tiene la secuencia de aminoácidos Gly-Phe-Thr-Phe-Ser-Ser-Tyr-Ala-Met-His; la CDR2 tiene la secuencia de aminoácidos Phe-lle-Trp-Asp-Asp-Gly-Ser-Phe-Lys-Tyr-Tyr-Ala-Glu-Ser-Val-Lys-Gly; la CDR3 tiene la secuencia de aminoácidos Glu-Gly-Ser- Trp-Ser-Pro-Asp-lle-Phe; la CDR1' tiene la secuencia de aminoácidos Ser-Gln-Gly-lle-Ser-Arg-Ala; la CDR2' tiene la secuencia de aminoácidos Asp-Ala-Ser; la CDR3' tiene la secuencia de aminoácidos Phe-Asn-Ser-Tyr-Pro-lle; b) la CDR1 tiene la secuencia de aminoácidos Gly-Phe-Thr-Leu-Phe-Ser-Ser-Phe-Gly-Met-His; la CDR2 tiene la secuencia de aminoácidos Val-lle-Trp-Tyr-Asp-Gly-Ser-Asn-Glu-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly; la CDR3 tiene la secuencia de aminoácidos Glu-Gly-Ser-Trp-Ser-Pro- Asp-lle-Phe; la CDR1' tiene la secuencia de aminoácidos Ser-Gln-Gly-lle-Arg-Ser-Ala; la CDR2' tiene la secuencia de aminoácidos Asp-Ala-Ser; la CDR3' tiene la secuencia de aminoácidos Phe-Asn-Ser-Tyr-Pro-Val; c) la CDR1 tiene la secuencia de aminoácidos Gly-Phe-Thr-Leu-Ser-Ser-Tyr-Gly-Met-His; la CDR2 tiene la secuencia de aminoácidos Val-lle-Trp-Tyr-Asp-Gly-Asn-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly; la CDR3 tiene la secuencia de aminoácidos Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe; la CDR1' tiene la secuencia de aminoácidos Ser-Gln-Gly-lle-Ser-Ser-Tyr; la CDR2' tiene la secuencia de aminoácidos Asp-Ala-Ser; la CDR3' tiene la secuencia de aminoácidos Phe-Asn-Ser-Tyr-Pro; d) la CDR1 tiene la secuencia de aminoácidos Gly-Asp-Thr-Phe- Ser-Ser-Tyr-Ala-lle-Ser; la CDR2 tiene la secuencia de aminoácidos Gly-lle-lle-lle-Pro-Val-lle-Gly-Thr-Val-Asn-Tyr-Glu-Glu-Arg-Phe-Gln-Asp-Arg; la CDR3 tiene la secuencia de aminoácidos Glu-Glu-Gly-Phe-Leu; la CDR1' tiene la secuencia de aminoácidos Ser-Gln-Gly-lle-Ser-Ser-Ala; la CDR2' tiene la secuencia de aminoácidos Asp-Ala-Ser; la CDR3' tiene la secuencia de aminoácidos Phe-Asn-Ser-Tyr-Pro-Leu; e) la CDR1 tiene la secuencia de aminoácidos Gly-Phe-Thr-Phe-Ser-Cys-Cys-Gly-Met-His; la CDR2 tiene la secuencia de aminoácidos Val-lle-Trp-Tyr-Asp-Gly-Ser-Asn-Lys-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly; la CDR3 tiene la secuencia de aminoácidos Asp-Ser-Ser-Gly-Ser-Phe-Tyr-Glu-Tyr-Phe; la CDR1' tiene la secuencia de aminoácidos Ser-Gln-Gly-lle-Asn- Ser-Ala; la CDR2' tiene la secuencia de aminoácidos Asp-Ala-Ser; la CDR3' tiene la secuencia de aminoácidos Phe-Asn-Ser-Tyr-Pro-Tyr; y f) la CDR1 tiene la secuencia de aminoácidos Gly-Phe-Thr-Phe-Ser-Gly-Tyr-Gly-Met-His; la CDR2 tiene la secuencia de aminoácidos Val-Val-Trp-Tyr-Asp-Gly-Gly-Tyr-Lys-Phe-Tyr-Ala-Asp-Ser-Val-Lys-Gly; la CDR3 tiene la secuencia de aminoácidos Asp-Ser-Ser-Gly-Ser-Phe-Tyr-Glu-Tyr-Leu; la CDR1' tiene la secuencia de aminoácidos Ser-Gln-Gly-lle-Ser-Ser-Ala; la CDR2' tiene la secuencia de aminoácidos Asp-Ala-Ser; la CDR3' tiene la secuencia de aminoácidos Phe-Asn-Ser-Tyr-Pro-His. Reivindicacion 15: El uso de la reivindicacion 14, en donde la enfermedad se selecciona a partir del grupo que consiste en dermatitis atopica, asma alérgico, y rinitis alérgica.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0417304A GB0417304D0 (en) | 2004-08-03 | 2004-08-03 | Organic compounds |
| GB0417303A GB0417303D0 (en) | 2004-08-03 | 2004-08-03 | Organic compounds |
| GB0417302A GB0417302D0 (en) | 2004-08-03 | 2004-08-03 | Organic compounds |
| GB0417305A GB0417305D0 (en) | 2004-08-03 | 2004-08-03 | Organic compounds |
| GB0417306A GB0417306D0 (en) | 2004-08-03 | 2004-08-03 | Organic compounds |
| GB0417301A GB0417301D0 (en) | 2004-08-03 | 2004-08-03 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050044A1 true AR050044A1 (es) | 2006-09-20 |
Family
ID=35457817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103199A AR050044A1 (es) | 2004-08-03 | 2005-08-01 | Anticuerpo especifico de il-4 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7740843B2 (es) |
| EP (2) | EP1817343B1 (es) |
| JP (1) | JP4808712B2 (es) |
| KR (1) | KR101245996B1 (es) |
| CN (1) | CN101001877B (es) |
| AR (1) | AR050044A1 (es) |
| AU (1) | AU2005268932B2 (es) |
| BR (1) | BRPI0514124B8 (es) |
| CA (1) | CA2574289C (es) |
| CY (1) | CY1115524T1 (es) |
| DK (1) | DK1817343T3 (es) |
| EC (1) | ECSP077222A (es) |
| ES (1) | ES2504415T3 (es) |
| HR (1) | HRP20140888T1 (es) |
| IL (1) | IL180789A (es) |
| MA (1) | MA28981B1 (es) |
| MX (1) | MX2007001342A (es) |
| MY (1) | MY141851A (es) |
| NO (1) | NO20070854L (es) |
| NZ (1) | NZ552637A (es) |
| PE (1) | PE20060560A1 (es) |
| PL (1) | PL1817343T3 (es) |
| PT (1) | PT1817343E (es) |
| SG (1) | SG155177A1 (es) |
| SI (1) | SI1817343T1 (es) |
| TN (1) | TNSN07036A1 (es) |
| TW (1) | TWI356828B (es) |
| WO (1) | WO2006013087A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1868647A4 (en) * | 2005-03-24 | 2009-04-01 | Millennium Pharm Inc | OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE |
| US8759490B2 (en) | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2009005673A1 (en) * | 2007-06-28 | 2009-01-08 | Schering Corporation | Anti-igf1r |
| BR112012027001A2 (pt) | 2010-04-23 | 2016-07-19 | Genentech Inc | produção de proteínas heteromultiméricas |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| BR112013019499B1 (pt) | 2011-02-04 | 2023-01-10 | Genentech, Inc. | Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante |
| EP3140392B1 (en) | 2014-05-06 | 2023-07-26 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins using mammalian cells |
| CA3023446A1 (en) | 2016-05-10 | 2017-11-16 | Hennepin Healthcare Research Institute | Cytokine signaling immunomodulators and methods |
| CN108409860B (zh) * | 2017-02-10 | 2021-10-15 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 |
| EP3655961A4 (en) * | 2017-07-17 | 2021-09-01 | Massachusetts Institute of Technology | HEALTHY AND SICK BARRIER TISSUE CELL ATLAS |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| MA55204A (fr) | 2019-03-06 | 2022-01-12 | Regeneron Pharma | Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer |
| SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CN111690066B (zh) * | 2020-06-22 | 2022-07-22 | 南京融捷康生物科技有限公司 | 抗IL-4Rα的单域抗体以及应用和药物 |
| CA3241374A1 (en) | 2021-12-30 | 2023-07-06 | Gregory GEBA | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| CN118388645B (zh) * | 2024-05-17 | 2024-11-22 | 康立泰生物医药(青岛)有限公司 | 一种抗人白介素4抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041381A (en) * | 1986-07-03 | 1991-08-20 | Schering Corporation | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| KR900700132A (ko) | 1988-02-02 | 1990-08-11 | 에릭 에스. 딕커 | 면역 글로불린 e 반응 억제 방법 |
| DE69026627T2 (de) * | 1989-12-20 | 1996-08-22 | Schering Corp., Kenilworth, N.J. | Antikörperantagonisten gegen humanes interleukin-4 |
| CA2130436C (en) * | 1992-02-19 | 2001-04-10 | John S. Abrams | Cloning and expression of humanized monoclonal antibodies against human interleukin-4 |
| ES2111769T3 (es) | 1992-08-20 | 1998-03-16 | Schering Corp | Nuevos usos de il-10. |
| AP583A (en) | 1993-09-07 | 1997-04-14 | Smithkline Beecham Corp | Recombination IL4 antibodies useful in treatment of IL4 mediated disorders. |
| US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5597710A (en) * | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US20020002132A1 (en) | 2000-05-26 | 2002-01-03 | Pluenneke John D. | Use of interleukin-4 antagonists and compositions thereof |
| NZ541050A (en) | 2002-12-16 | 2010-06-25 | Genmab As | Human monoclonal antibodies against interleukin 8 (IL-8) |
| FR2859725B1 (fr) * | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
-
2005
- 2005-08-01 PE PE2005000884A patent/PE20060560A1/es not_active Application Discontinuation
- 2005-08-01 AR ARP050103199A patent/AR050044A1/es not_active Application Discontinuation
- 2005-08-02 SI SI200531872T patent/SI1817343T1/sl unknown
- 2005-08-02 KR KR1020077002715A patent/KR101245996B1/ko not_active Expired - Fee Related
- 2005-08-02 HR HRP20140888TT patent/HRP20140888T1/hr unknown
- 2005-08-02 MX MX2007001342A patent/MX2007001342A/es active IP Right Grant
- 2005-08-02 EP EP05769838.3A patent/EP1817343B1/en not_active Expired - Lifetime
- 2005-08-02 CN CN2005800260794A patent/CN101001877B/zh not_active Expired - Fee Related
- 2005-08-02 PT PT57698383T patent/PT1817343E/pt unknown
- 2005-08-02 AU AU2005268932A patent/AU2005268932B2/en not_active Ceased
- 2005-08-02 CA CA2574289A patent/CA2574289C/en not_active Expired - Fee Related
- 2005-08-02 TW TW094126210A patent/TWI356828B/zh not_active IP Right Cessation
- 2005-08-02 DK DK05769838.3T patent/DK1817343T3/da active
- 2005-08-02 NZ NZ552637A patent/NZ552637A/en not_active IP Right Cessation
- 2005-08-02 ES ES05769838.3T patent/ES2504415T3/es not_active Expired - Lifetime
- 2005-08-02 MY MYPI20053585A patent/MY141851A/en unknown
- 2005-08-02 BR BRPI0514124A patent/BRPI0514124B8/pt not_active IP Right Cessation
- 2005-08-02 US US11/632,939 patent/US7740843B2/en not_active Expired - Fee Related
- 2005-08-02 JP JP2007524263A patent/JP4808712B2/ja not_active Expired - Fee Related
- 2005-08-02 SG SG200905152-5A patent/SG155177A1/en unknown
- 2005-08-02 WO PCT/EP2005/008361 patent/WO2006013087A1/en not_active Ceased
- 2005-08-02 PL PL05769838T patent/PL1817343T3/pl unknown
- 2005-08-02 EP EP10180854A patent/EP2327726A3/en not_active Withdrawn
-
2007
- 2007-01-18 IL IL180789A patent/IL180789A/en not_active IP Right Cessation
- 2007-02-02 TN TNP2007000036A patent/TNSN07036A1/en unknown
- 2007-02-02 EC EC2007007222A patent/ECSP077222A/es unknown
- 2007-02-14 NO NO20070854A patent/NO20070854L/no not_active Application Discontinuation
- 2007-02-22 MA MA29708A patent/MA28981B1/fr unknown
-
2010
- 2010-04-15 US US12/760,891 patent/US20100254993A1/en not_active Abandoned
-
2014
- 2014-09-05 CY CY20141100716T patent/CY1115524T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050044A1 (es) | Anticuerpo especifico de il-4 | |
| ES2547463T3 (es) | Moléculas de unión a ILT3 y usos de las mismas | |
| PE20050925A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| AR065921A1 (es) | Anticuerpos anti-ige | |
| MX392340B (es) | Anticuerpo anti cd73 humana. | |
| AR085600A1 (es) | Agentes de union biespecifica | |
| CO6231009A2 (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| DE602005025525D1 (de) | Vollständige humane monoklonale antikörper gegen il-13 | |
| PE20030104A1 (es) | Anticuerpos humanos para cd154 | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| DE60333228D1 (de) | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen | |
| ECSP11010911A (es) | Anticuerpos contra la il17 humana y usos de los mismos | |
| AR063829A1 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
| TW200716182A (en) | Antibodies directed to CD20 and uses thereof | |
| UY30260A1 (es) | Anticuerpos dirigidos contra upar y usos de los mismos | |
| EA200800812A1 (ru) | Композиции антитела против cd3 | |
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| EP2361933A3 (en) | Antibodies against interleukin-1 beta | |
| DE60325906D1 (de) | Antikörper gegen parath-hormon (pth) und ihre verwendungen | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| UY29288A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
| PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| RU2010133547A (ru) | Анти-cldn антитела | |
| JP2017508475A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |